The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Merck has also decided to end the favezelimab clinical development program
SPARC to receive 55% equity in Tiller Therapeutics
First and only PARP inhibitor to improve overall survival in early breast cancer
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
The company uses iPS cells to develop treatments for diseases relating to the kidney
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
